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Available online xxxxObjective:The objective of the studywas to characterize the prevalence of polypharmacy and central nervous sys-
tem (CNS)-acting medications in patients with epilepsy, and particular types of medications.
Methods: This was a retrospective cross-sectional study using data from the nationally representative National
Health and Nutrition Examination Survey (NHANES).We included patientswho reported taking at least one pre-
scriptionmedication in order to treat seizures or epilepsy during NHANES survey years 2013–2016.We assessed
the number and types of drugs and predictors of total number of medications using a negative binomial regres-
sion. We then assessed prevalence of polypharmacy (≥5 medications), CNS polypharmacy (≥3 CNS-acting med-
ications) and additional CNS-actingmedications, and drugs that lower the seizure threshold (i.e., bupropion and
tramadol), and extrapolated prevalence to estimated affected US population.
Results: The NHANES contained 20,146 participants, of whom 135 reported taking ≥1 antiseizure medication
(ASM) for seizures or epilepsy representing 2,399,520 US citizens using NHANES's sampling frame. Patients re-
ported taking a mean 5.3 (95% confidence interval (CI): 4.3–6.3) prescription medications. Adjusting for race,
sex, and uninsurance, both age and number of chronic conditions predicted increased number of medications
(incident rate ratio (IRR) per decade: 1.16, 95% CI: 1.04–1.28; IRR per chronic condition: 1.19, 95% CI: 1.11–
1.27). Polypharmacy was reported by 47% (95% CI: 38%–57%) of patients, CNS polypharmacy by 34% (23%–
47%), benzodiazepine use by 21% (14%–30%), opioid use by 16% (11%–24%), benzodiazepine plus opioid use by
6% (3%–14%), and 6% (2%–15%) reported a drug that lowers the seizure threshold. Twelve percent (7%–20%)
took an opioid with either a benzodiazepine or gabapentinoid.
Conclusions: Polypharmacy is common in patients with epilepsy. Patients taking ASMs frequently reported also
taking other CNS-acting medications (i.e., opioids, benzodiazepines, seizure threshold-lowering medications),
and medication combinations with black box warnings. Central nervous system polypharmacy poses health
risks. Future research is needed to explore drivers of polypharmacy and strategies to help mitigate potentially
harmful prescription use in this high-risk population.
© 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).Keywords:
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Patients with epilepsy experience a high degree of comorbidity [1],
and comorbidities drive polypharmacy [2].Whilemultiple prescriptions
may be appropriate for patients with many chronic conditions, more
prescriptions also create the potential for inappropriate prescribing
[3], which is associatedwith adverse outcomes such as poor health, hos-
pitalization, and death [4–9]. Patients with epilepsy are known to have
increased risk formedication self-poisoning especially related to opioidser the CC BY license (http://creativecommons.org/licenses/by/4.0/).
2 S.W. Terman et al. / Epilepsy & Behavior 111 (2020) 107261and psychotropic medications [10]. Moreover, one study found among
patients with epilepsy that 25% of variance in quality of life was ex-
plained simply by medication adverse effects [11].
While patients with epilepsy likely experience a high burden of
polypharmacy, the extent of the problem is poorly understood. Only lim-
ited data exist describing the frequency and composition of polypharmacy
and central nervous system (CNS)-acting medications taken by patients
with epilepsy beyond simply antiseizure medications (ASMs) [12–15].
However, certain knowledge gaps exist. No nationally representative
data exist in the US regarding polypharmacy in patients with epilepsy.
Furthermore, these prior studies did not explicitly capture particularly im-
portant medication combinations such as seizure threshold-lowering
medications or certain ‘black box warnings’ including combinations of
opioids and benzodiazepines or gabapentinoids. Finally, such studies
more narrowly defined ‘polypharmacy’ or ‘concomitant medications’ as
N1 ASM or 1 ASM plus ≥1 non-ASM, whereas general medical literature
more typically defines polypharmacy in broader terms of total number
of medications exceeding a certain threshold such as ≥5 medications
[16,17]. Thus,we currently lack awider-viewexaminationof total number
of prescription medications and relevant potentially dangerous combina-
tions taken by people with epilepsy especially in the US. Further charac-
terizing the regimens currently prescribed to patients with epilepsy
including but also beyond ASMs is a critical step towards future investiga-
tion aimed at identifying potentially inappropriate drug treatments and
reducing adverse effects from complex CNS polypharmacy.
In this study, we used nationally representative US survey data to
describe the number and types of prescription medications used by pa-
tientswith epilepsy. First, we described the total number ofmedications
and examined several a priori specified key predictors. Then, we studied
the frequency of polypharmacy overall. Finally, given unique risks of
CNS-activemedications and particular drug–drug combinations, we ex-
amined the frequency of CNS polypharmacy, opioids, benzodiazepines,
gabapentinoids, medications known to lower the seizure threshold,
and several combinations with known hazards.
2. Methods
2.1. Study design and dataset
This was a cross-sectional analysis of the National Health and Nutri-
tion Examination Survey (NHANES) using data collected from 2013 to
2016 during which participants were asked for the indications of each
prescription medication. The NHANES is a long-standing semiannual
cross-sectional study run by the Centers for Disease Control and Preven-
tion. Its goal is to understand broad trends in health and nutrition in the
United States. The NHANES samples approximately 5000–10,000 nonin-
stitutionalized individuals from 15 counties across the US each year and
oversamples certain individuals (over 60 years old, African Americans,
Hispanics) selected from theUSCensus to ensure it is nationally represen-
tative. It uses complex, stratified, multistage probability cluster sampling
and collects data including respondents' prescribed medications and
health conditions. Health interviews are conducted in a participant's
home, and in-person physical examination by a physician is conducted
in a traveling mobile center. The design and operation of NHANES are
available online (https://wwwn.cdc.gov/nchs/nhanes/default.aspx).
2.2. Procedures involving human subjects
This study was deemed exempt by the University of Michigan Insti-
tutional Review Board, given use of publicly available deidentified
datasets.
2.3. Patient selection
The NHANES collects information about all participants' prescription
medications. Each participant listed the name of each medication theyhave taken in the last 30days prescribedby a health professional. Partic-
ipants provided up to 3 main reasons for using each medication.
We limited analysis to survey participants who responded that they
were taking at least one medication for “epilepsy and recurrent sei-
zures” (G40). We confirmed that each medication was a standard
ASM. If amedicationwas coded as G40 but not actually an ASMbyman-
ual review, we converted the International Classification of Diseases
(ICD) indication to blank and did not count such medications towards
our case definition.
2.4. Variables
We collected baseline variables related to polypharmacy in order to
describe our population [2]. Demographics included age, sex, and race.
Income-to-poverty ratio represents a family's income as a ratio of pov-
erty guidelines. Participants reportedwhether a healthcare professional
had diagnosed a variety of conditions including asthma, chronic ob-
structive pulmonary disease, congestive heart failure, coronary disease,
hypertension, diabetes, liver disease, thyroid disease, and malignancy.
Epilepsy was not specifically asked about in this section. For the defini-
tion of hypertension and diabetes, we required that participants either
reported at least one medication treating these conditions, or else
NHANES measurements suggested the diagnosis (hypertension:
systolic blood pressure (SBP) N 140 or diastolic blood pressure (DBP) N
90 averaged over 3 measures; diabetes: A1c N 7%) as has been done in
prior NHANES studies [18]. Patients also completed a Patient Health
Questionnaire-9 (PHQ9) to evaluate depression severity at the time of
the survey. Other variables included insurance coverage, household in-
come, and self-reported health status.
2.5. Statistical analysis
For categorical data,we report rawcounts and survey-weighted pro-
portions and 95% confidence intervals (CIs). For continuous data, we re-
port survey-weighted means plus standard deviation (SD) or 95% CIs.
The weights provided in each biennial cycle's dataset were divided by
2 (the number of interview cycles we have used: 2013–2014 and
2015–2016), so that the estimates are nationally representative of the
US population across the four-year time period [19].
For our main analysis, we counted each patient's total number of re-
ported medications. We report the most common medication names,
therapeutic category and primary disease systems using Multum Lexi-
con®, and patient-reported indications. We then performed several
analyses identifying predictors of total medication count. First, we
displayed scatterplots of total number medications according to two
prespecified predictors identified based on literature [2] and theoretical
importance — age, and total number of chronic conditions. Second, we
performed an adjusted regression to assess the association between
these variables and total number of medications. To accomplish this,
we conducted a survey-weighted zero-truncated negative binominal
regression. In this model, the total number of medications was the out-
come variable, and predictors included age and number of chronic con-
ditions, adjusted also for race, uninsurance, and sex. The chosen model
was a negative binomial regression given medication data were
overdispersed and zero-truncated given all participants entering this
study by definition reported at least 1medication. After analyzingmed-
ication count as a continuous variable, we classified this number as
polypharmacy (5 or more) and also at least 10 medications [16,17].
We further explored a priori particular types and combinations of
medications. We applied the Multum Lexicon® to define opioids and
benzodiazepines given their special importance in polypharmacy. We
flagged whether benzodiazepines were prescribed for epilepsy, versus
a nonseizure indication. We defined CNS polypharmacy as at least 3
CNS-actingmedications, according to updatedBeers criteria [20,21]. An-
tiseizuremedicationswere counted towards this definition (thus, all pa-
tients in this study were on at least 1 CNS-acting medication), in
Table 1
Population description. N = 135.
Mean (SD) or No. (%)a
Demographics Age 51 (15)
Male sex 75 (58%)
Race
Mexican American 17 (8%)
Non-Hispanic black 21 (8%)
Non-Hispanic white 62 (70%)
Uninsured 12 (8%)
Family income to poverty ratiob 1.7 (1.4)
Comorbiditiesc Asthma 33 (26%)
Cancer 18 (16%)
Chronic obstructive pulmonary disease 21 (23%)
Congestive heart failure 7 (14%)
Coronary disease 6 (11%)
Diabetes mellitus 17 (14%)
Hypertension 51 (38%)
Liver disease 7 (11%)
Patient Health Questionnaire 9 (PHQ9)d 5.6 (5.7)
Stroke 21 (19%)
Thyroid disease 17 (20%)
Number chronic conditions 3.8 (2.8)
a Frequencies are raw counts. All means (SD) and percentages are weighted according
to the NHANES sampling frame. Variables have 0% missingness for those raw N= 135 in
the sample except as stated below.
b Income had weighted 6% missing data (raw included N/raw eligible N = 125/135).
c Comorbidities were only asked of patients at least 20 years old, with 0%missing (raw
included N/raw eligible N = 99/99).
d PHQ9 was asked of those at least 18 years old, with weighted 19% missing data (raw
included N/raw eligible N = 81/104). Common interpretation thresholds for depression
include 0–4minimal, 5–9mild, 10–14moderate, 15–19moderately severe, and 20–27 se-
vere [55].
3S.W. Terman et al. / Epilepsy & Behavior 111 (2020) 107261addition to antipsychotics, benzodiazepines, nonbenzodiazepine ben-
zodiazepine receptor agonists, tricyclic antidepressants, selective sero-
tonin reuptake inhibitors (SSRIs), selective serotonin–norepinephrine
reuptake inhibitors (SNRIs), or opioids. We lastly evaluated particular
disease–drug interactions (including common medications known to
lower the seizure threshold: tramadol [22,23] and bupropion [24,25])
plus several drug–drug combinations with black box warnings from
the US Food and Drug Administration (opioid-benzodiazepine [26];
opioid-gabapentinoid [27]). We calculated the survey-weighted
percentage of our sample taking each of the above medications or com-
binations and multiplied this percentage times the total US population
represented by our included participants to estimates the involved US
population accounting for NHANES's complex survey weighting design.
Data were analyzed using SAS 9.4 (Cary, NC) and Stata 14.2 (College
Station, TX).
2.6. Data accessibility statement
All datasets are freely available for download at https://wwwn.cdc.
gov/nchs/nhanes/Default.aspx.
3. Results
Combining the 2013–2014 and 2015–2016 NHANES samples, there
were 20,146 participants. Of these, 136 (0.7%) had at least one medica-
tion reported for “epilepsy and recurrent seizures”. Three participants
reported medications for “epilepsy and recurrent seizures”, which
were not actually an ASM: hydrocodone, allopurinol, and apixaban.
Two of these 3 cases were still included because they endorsed at
least 1 other true ASM for “epilepsy and recurrent seizures.” The re-
maining casewas excluded because therewas no trueASM for “epilepsy
and recurrent seizures.” Thus, our final sample size was 135 (raw pro-
portion: 135/20,146 = 0.7%; survey-weighted proportion: 0.8%, 95%
CI: 0.6%–0.9%) representing 2,399,520 US citizens using NHANES's sam-
pling frame.
The mean age was 51 (SD: 15), 58% were male, 70% were non-His-
panic white, and 8% were uninsured. The mean number of nonepilepsy
comorbidities of those listed available in NHANES was 3.8 (SD: 2.8)
(Table 1). Of the 135 participants, 70% (95% CI: 55%–79%) reported
one ASM, 21% (14%–29%) two ASMs, 6% (2%–19%) three ASMs, and 3%
(1%–15%) four ASMs. The most common medications, indications, and
medication classes are shown in Supplemental Tables 1, 2, and 3,
respectively.
Themean number of total prescriptionmedicationswas 5.3 (95% CI:
4.3–6.3). Fig. 1 depicts the distribution of total medications in our sam-
ple. Excluding ASMs, themean (95% CI) number of medications was 3.8
(2.8–4.8). Fig. 2 contains scatterplots depicting the bivariate relation-
ship between total prescriptionmedications and the following two var-
iables: age and number of nonepilepsy chronic conditions. Table 2
displays results from a zero-truncated negative binomial regression in-
cluding each of the following predictors: age, number of nonepilepsy
chronic conditions, race, uninsurance, and sex. For every decade, there
was a 16% increase in number of medications (incident rate ratio
(IRR): 1.16; 95% CI: 1.04–1.28). For every additional chronic condition,
there was a 19% increase (IRR: 1.19; 95% CI: 1.11–1.27). Fig. 3 shows
good model calibration between observed and expected values across
deciles of predicted medication count.
Table 3 demonstrates prevalence of polypharmacy (≥5medications)
as a dichotomous variable and our a priori specific medications and
medication combinations of interest. Forty-seven percent (95% CI:
38%–57%) of participants met criteria for polypharmacy and 17% (9%–
32%) for at least 10 medications. Using NHANES's sampling frame,
these frequencies extrapolate to 1,137,612 US citizens treated for epi-
lepsy taking 5 or more medications, which includes 419,676 taking 10
or more medications. Twenty-one percent (95% CI: 14%–30%) of partic-
ipants reported at least one benzodiazepine, 16% (11%–24%) at least oneopioid, and 6% (2%–15%) at least one medication known to lower the
seizure threshold (bupropion 2%; tramadol 4%). Regarding specific
drug combinations, 6% (3%–14%) reported an opioid plus benzodiaze-
pine, 7% (4%–13%) an opioid plus gabapentinoid, and 34% (23%–47%)
CNS polypharmacy. Table 3 also displays in absolute terms how many
US citizens each of these percentages represent; for example, this repre-
sents 502,219 US citizens using a benzodiazepine, 386,802 using an opi-
oid, and 819,436 fulfilling criteria for CNS polypharmacy.
4. Discussion
In a nationally representative sample, we found that patients treated
for epilepsy took an average 5.3 medications, which increased with age
and chronic condition burden. Approximately half met criteria for
polypharmacy, 17% reported at least 10 medications, and 34% had CNS
polypharmacy.We documented that 21% reported at least 1 benzodiaz-
epine, 16% reported at least one opioid, 12% reported an opioid in com-
bination with either a benzodiazepine or gabapentinoid despite the
combinations' known danger, and 6% reported at least one medication
known to lower the seizure threshold. Extrapolating to the US popula-
tion using NHANES's sampling frame, these frequencies represent ap-
proximately 1.1 million US citizens treated for epilepsy taking 5 or
more medications. This estimate includes over 500,000 using at least 1
benzodiazepine, 387,000 using at least 1 opioid, 248,000 using a black
box warning opioid combination, 150,000 taking medications known
to lower the seizure threshold (tramadol, bupropion), and 819,000
using at least 3 CNS-acting medications. These results suggest that siz-
able numbers of patientswith epilepsy are potentially at risk for adverse
effects from polypharmacy.
These findings are concerning. Prior work has shown that patients
with epilepsy demonstrate 3–5 times increasedmedication self-poison-
ing comparedwith populationswithout epilepsy [10]. In that study, opi-
oids and psychotropic medications were more commonly involved in
poisoning-related deaths than ASMs, which underscores the impor-
tance of monitoring pharmacoepidemiology more broadly than just
ASMs in patients with epilepsy. In line with this observation, over
Fig. 1. Distribution of total medications. Frequencies (%) are weighted. Counts (N) above each bar are raw.
4 S.W. Terman et al. / Epilepsy & Behavior 111 (2020) 10726170,000 deaths occur each year in the US due to drug overdose, and two-
thirds of these are related to opioids [28]. A prior study using all
NHANES participants [29] estimated 7% of US adults took an opioid.
The 16% (95% CI: 11%–24%) prevalence of opioids in our study suggests
that opioid use is increased in patients with epilepsy. In a privately in-
sured population, prevalence of opioid use was 26% with epilepsy ver-
sus 18% without epilepsy [12]. Opioids were the second most common
class of medications among patients with epilepsy after ASMs [13]. In
their study, consistent with prior work [30], patients with epilepsy did
demonstrate increased pain and psychiatric conditions that could
drive this relationship. Our study expands upon this prior work by uti-
lizing a nationally representative dataset that includes uninsured pa-
tients, explores important drug combinations, and captures drugs that
lower the seizure threshold and particularly CNS polypharmacy. Given
themagnitude of the problem, future attention needs to focus onmech-
anisms driving high opioid usage among patients with epilepsy and the
development of alternative strategies for analgesia.
Benzodiazepine use is likewise common and potentially harmful
because of potential dependence, somnolence, and respiratory
suppression [31]. Approximately 5–10% of US adults are prescribed a
benzodiazepine [32,33]. Increased anxiety and depression in patientsFig. 2.Bivariate relationship between totalmedications andA) age (N=135) and B) number of
≥20 years old). The horizontal line at Y = 5 denotes the cutoff at/above which participants are
overlapping data points (i.e., number of chronic conditions take on integer values). Number of ch
pulmonary disease, congestive heart failure, coronary disease, hypertension, diabetes, liver d
hypertension and diabetes whose definitions also included blood pressure or A1c measuremenwith epilepsy [34] could explain increased benzodiazepine use. We
did find that most benzodiazepines in this study were used to treat sei-
zures. While benzodiazepines are indicated for acute seizure treatment
and can be effective for seizure reduction, our study nonetheless high-
lights that prescribersmust remain cognizant of a patient's overall med-
ication regimen in order to avoid potentially harmful interactions.
Additionally, we found 12% of participants combined opioids with a
gabapentinoid or benzodiazepine, despite a current black box warning.
For example, opioids plus benzodiazepines pose well-known risk: 23%
of opioid-related overdoses also involve benzodiazepines, concurrent
use elevates risk for emergency room (ER) use and hospitalization
[35], and overdose death rates are 10 times higher for those
coprescribed opioids and benzodiazepines compared with those pre-
scribed opioids alone [36].
This study highlights the broader issue of CNS polypharmacy. An es-
timated 4 million outpatient visits with CNS polypharmacy occur each
year for patients 65 years and older, which has been rising over time
[21], and literature has documented cumulative toxicity and drug inter-
actions due to CNS polypharmacy [37,38]. Prior work has provided im-
portant background information; for example, one large study in
Norway found 37% of patients on an ASM used at least 1 other ASM,chronic conditions (N=99, given chronic conditionswere only obtained fromparticipants
classified as having polypharmacy. Note there is a small amount of jitter for display given
ronic conditionswas calculated as the sumof the following conditions: chronic obstructive
isease, thyroid disease, and malignancy. These conditions were self-reported, except for
t, or else pharmacotherapy as reported in the Methods section.
Table 2
Predictors of total number of medications. N = 99. The following displays results from a
survey-weighted zero-truncated negative binomial regression. This model estimates the
incident rate ratio for each predictor adjusted for all other listed predictors, on total num-
ber of medications. Estimates may be interpreted as the relative increase in total number
of medications for each 1-unit change in the listed predictor, adjusted for all others. Note
that only participants ≥20 years old (N= 99) provided responses to listed chronic condi-
tions, out of our total study population (N = 135).
IRR % (95% CI)a
Age, decade 1.16 (1.04–1.28)⁎
Number of chronic conditionsb 1.19 (1.11–1.27)⁎
Race Non-Hispanic white Ref
Non-Hispanic Black 0.90 (0.63–1.30)
Mexican American 1.11 (0.75–1.66)
Other Hispanic 0.76 (0.46–1.23)
Uninsured 1.03 (0.79–1.37)
Male 1.11 (0.83–1.49)
a All estimates are adjusted for each of the other listed variables.
b Number of chronic conditions was calculated as the sum of the following conditions:
chronic obstructive pulmonary disease, congestive heart failure, coronary disease, hyper-
tension, diabetes, liver disease, thyroid disease, and malignancy. These conditions were
self-reported, except for hypertension and diabetes whose definitions also included blood
pressure or A1c measurement, or else pharmacotherapy as reported in the methods
section.
⁎ p b 0.05.
Fig. 3. Model calibration. For the survey-weighted zero-truncated negative binomial
regression, we modeled how total medications was predicted by age, number of chronic
conditions, race, uninsurance, and sex (N = 99). To assess model fit, we calculated
predicted total medication count from the model, and in this figure plot, the observed
and expected medication count for each decile of predicted medication count. This
figure shows the model demonstrates good calibration across the population.
Table 3
Specific medications.
Overall ≥5 medications (polypharmacy)
≥10 medications
Specific medications ≥1 benzodiazepine
≥1 benzodiazepine, not for epilepsy or seizures
≥1 opioid
Bupropion
Tramadol
Medication combinations Opioid plus benzodiazepine
Opioid plus gabapentinoid
Opioid plus either benzodiazepine or gabapentinoi
CNS polypharmacyb
a Weighted number refers to theweighted percentage (% from themiddle column) times the
2,399,520 US citizens per NHANES's sampling frame.
b CNS polypharmacy: At least 3 CNS-acting medications including antiepileptics, antipsycho
pressant, selective serotonin reuptake inhibitor, selective serotonin–norepinephrine reuptake i
5S.W. Terman et al. / Epilepsy & Behavior 111 (2020) 107261antidepressant, or antipsychotic [15]. Our study builds upon this prior
work, and other work examining prevalence of concomitant medica-
tions taken alongside ASMs [14], because our study captured
polypharmacy as more broadly defined in the medical literature, and
identified particular dangerousmedication combinations and drug–dis-
ease interactions that were not described in prior studies. Of course,
many patients have legitimate indications formultiple CNS-actingmed-
ications, and in each situation, the neuropsychiatric benefits must be
weighed against additive risk. However, exploring CNS polypharmacy
aswe have done here is particularly useful to shed light on a potentially
modifiable source of adverse outcomes.
Finally, it is worth noting that ASMs comprised the largest group of
medication in this study. We did define epilepsy according to ASM use,
so this result is expected. Nonetheless, ASMs are the mainstay of treat-
ment for epilepsy and contribute substantially to CNS polypharmacy. Ad-
verse effects of ASMs range from 10 to 40% of patients in unstructured
screening to as high as 60–90% [39] in structured screenings, and adverse
effects are correlated with worsened quality of life [40–43]. This under-
scores the need to carefully consider if andwhenASMs are no longer nec-
essary. Two-thirds of patients with epilepsy are well-controlled on
medications [44] and may be candidates for ASM withdrawal [45], and
ASM discontinuation for seizure-free patients has been associated with
improvement in key outcomes such as mood [46], cognition [47–49],
and psychosocial well-being [50]. Accordingly, ASM treatment decisions
represent a ready lever under the clinician's control.
This study has several limitations. Inclusion criteria were based on
self-reported treatment indications, which could misclassify patients.
For example, our inclusion criteria based on available data (taking ≥1
ASM for seizures or epilepsy) may not have captured all patients with
epilepsy; patients with well-controlled epilepsy may eventually appro-
priately discontinue their ASM [45] or else patientsmay inappropriately
not receive an ASM despite it being indicated (the “treatment gap”)
[51]. However, we believe that this is a reasonable definition because
identification of epilepsy by self-report has been validatedwith positive
predictive value of 74% and sensitivity of 84% [52], and the presence of
an ASM has been shown to substantially improve detection of epilepsy
in research datasets [53], data exist validating accuracy of self-reported
analgesia use [54], and ASMs are themainstay of treatment for epilepsy.
Self-report actually presents a distinct advantage: whereas chart listing
or prescription claims suggest a patient has been prescribed a medica-
tion, self-report reflects what a patient has actually been taking. Second,
our data do not distinguish between intermittent rescue versus daily
chronic use of benzodiazepine or opioids. Third, our sample size of
135 participants leads to certain estimates having wide confidence in-
tervals, for example, seizure threshold-lowering drugs. Nonetheless,
these 135 participants actually extrapolate to 2.4 million US individuals
given NHANES's complex, careful sampling design, which is a major
strength.Raw no. Weighted % (95% CI) Weighted no.a
63 47% (38%–57%) 1,137,612
19 17% (9%–32%) 419,676
30 21% (14%–30%) 502,219
11 7% (3%–14%) 162,207
23 16% (11%–24%) 386,802
1 2% (b1%–14%) 50,629
8 4% (2%–11%) 100,539
8 6% (3%–14%) 147,330
7 7% (4%–13%) 166,047
d 14 12% (7%–20%) 248,830
47 34% (23%–47%) 819,436
weighted sample (N=2,399,520). This is because the 135 included participants represent
tic, benzodiazepine, nonbenzodiazepine benzodiazepine receptor agonist, tricyclic antide-
nhibitor, and opioids, as defined in Beers criteria [20].
6 S.W. Terman et al. / Epilepsy & Behavior 111 (2020) 1072615. Conclusions
Medication burden is high in patients with epilepsy. This includes
overall polypharmacy, CNS polypharmacy, and both potential drug–
drug and drug–disease interactions. Future work is needed to clarify
the drivers of polypharmacy in epilepsy, further understand down-
streameffects of polypharmacy in this group, and develop interventions
to reduce potentially inappropriate or harmful medication burden in
this high-risk population.
Author contributions
Dr. Terman contributed to hypothesis generation, study design, data
collection, statistical analysis, andmanuscript preparation. All other au-
thors contributed to study design and manuscript preparation and
editing.
Study funding
Dr. Terman is supported by the University of Michigan Department
of Neurology Training Grant 5T32NS007222-38. He has no relevant
disclosures.
Dr. Aubert is supported by Schweizerischer Nationalfonds zur
Förderung der Wissenschaftlichen grant P2LAP3_184042.
Dr. Hill is supported by National Institutes of Health KL2TR002241.
Dr. Maust is supported by the National Institute on Drug Abuse
R01DA045705.
Dr. Betjemann has received compensation for serving as web editor
of JAMA Neurology and as a consultant to Marinus Pharmaceutics and
the National Football League.
Dr. Boyd is supported by National Institutes of Health, National Insti-
tute of Aging K24AG056578 and R24AG064025.
Dr. Burke is supported by National Institute of Neurological Disor-
ders and Stroke K08 NS082597 and National Institutes of Health Na-
tional Institute on Minority Health and Health Disparities R01
MD008879.
These sponsors did not have any role in the study design, or in the
collection, analysis or interpretation of data, in thewriting of the report,
or in the decision to submit the article for publication.
Declaration of competing interest
None of the authors has any competing interest to disclose.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.yebeh.2020.107261.
References
[1] Weatherburn CJ, Heath CA, Mercer SW, Guthrie B. Physical and mental health co-
morbidities of epilepsy: population-based cross-sectional analysis of 1.5 million
people in Scotland. Seizure. 2017;45:125–31. https://doi.org/10.1016/j.seizure.
2016.11.013.
[2] Hovstadius B, Petersson G. Factors leading to excessive polypharmacy. Clin Geriatr
Med. 2012;28:159–72. https://doi.org/10.1016/j.cger.2012.01.001.
[3] Opondo D, Eslami S, Visscher S, De Rooij SE, Verheij R, Korevaar JC, et al. Inappropri-
ateness of medication prescriptions to elderly patients in the primary care setting: a
systematic review. PLoS One. 2012;7. https://doi.org/10.1371/journal.pone.0043617.
[4] Field TS, Gurwitz JH, Avorn J, McCormick D, Jain S, Eckler M, et al. Risk factors for ad-
verse drug events among nursing home residents. Arch Int Med. 2001;161:1629–34.
[5] Wimmer BC, Cross AJ, Jokanovic N, Wiese MD, George J, Johnell K, et al. Clinical out-
comes associated withmedication regimen complexity in older people: a systematic
review. J Am Geriatr Soc. 2017;65:747–53. https://doi.org/10.1111/jgs.14682.
[6] Rawle MJ, Richards M, Cooper R, Kuh D. Associations between polypharmacy and
cognitive and physical capability: a British Birth Cohort Study. J Am Geriatr Soc.
2018;66:916–23. https://doi.org/10.1111/jgs.15317.
[7] Gnjidic D, Hilmer SN, Blyth FM, Naganathan V, Waite L, Seibel MJ, et al.
Polypharmacy cutoff and outcomes: five or more medicines were used to identifycommunity-dwelling older men at risk of different adverse outcomes. J Clin
Epidemiol. 2012;65:989–95. https://doi.org/10.1016/j.jclinepi.2012.02.018.
[8] Budnitz DS, LovegroveMC, Shehab N, Richards CL. Emergency hospitalization for ad-
verse drug events in older Americans. N Engl J Med. 2011;365:2002–12. https://doi.
org/10.1097/01.sa.0000412401.21757.36.
[9] Shehab N, Lovegrove MC, Geller AI, Rose KO, Weidle NJ, Budnitz DS. US emergency
department visits for outpatient adverse drug events, 2013–2014. JAMA. 2016;
316:2115–25. https://doi.org/10.1001/jama.2016.16201.
[10] Gorton HC, Webb RT, Carr MJ, DelPozo-Banos M, John A, Ashcroft DM. Risk of unnat-
ural mortality in people with epilepsy. JAMA Neurol. 2018;75:929–38. https://doi.
org/10.1001/jamaneurol.2018.0333.
[11] Zou X, Hong Z, Chen J, Zhou D. Is antiepileptic drug withdrawal status related to
quality of life in seizure-free adult patients with epilepsy? Epilepsy Behav. 2014;
31:129–35. https://doi.org/10.1016/j.yebeh.2013.11.028.
[12] Wilner AN, Sharma BK, Thompson AR, Krueger A. Analgesic opioid use in a health-
insured epilepsy population during 2012. Epilepsy Behav. 2016;57:126–32.
https://doi.org/10.1016/j.yebeh.2016.01.033.
[13] Wilner AN, Sharma BK, Thompson A, Soucy A, Krueger A. Diagnoses, procedures,
drug utilization, comorbidities, and cost of health care for people with epilepsy in
2012. Epilepsy Behav. 2014;41:83–90. https://doi.org/10.1016/j.yebeh.2014.08.131.
[14] Majkowska-Zwolińska B, Jdrzejczak J, Majkowski J. Use and costs of concomitant
medicines in epileptic patients in Poland: a 12-month prospective multicentre
study. Seizure. 2011;20:673–8. https://doi.org/10.1016/j.seizure.2011.06.015.
[15] Baftiu A, Feet SA, Larsson PG, Burns ML, Henning O, Sætre E, et al. Utilisation and
polypharmacy aspects of antiepileptic drugs in elderly versus younger patients
with epilepsy: a pharmacoepidemiological study of CNS-active drugs in Norway,
2004–2015. Epilepsy Res. 2018;139:35–42. https://doi.org/10.1016/j.eplepsyres.
2017.11.001.
[16] Hajjar ER, Hanlon JT, Sloane RJ, Lindblad CI, Pieper CF, Ruby CM, et al. Unnecessary
drug use in frail older people at hospital discharge. J Am Geriatr Soc. 2005;53:
1518–23. https://doi.org/10.1111/j.1532-5415.2005.53523.x.
[17] Masnoon N, Shakib S, Kalisch-ellett L, Caughey GE. What is polypharmacy? A sys-
tematic review of definitions. 2017:1–10. https://doi.org/10.1186/s12877-017-
0621-2.
[18] Muntner P, DeSalvo KB, Wildman RP, Raggi P, He J, Whelton PK. Trends in the prev-
alence, awareness, treatment, and control of cardiovascular disease risk factors
among noninstitutionalized patients with a history of myocardial infarction and
stroke. Am J Epidemiol. 2006;163:913–20 https://doi.org/kwj124 [pii].
[19] National Health and Nutrition Examination Survey: Analytic Guidelines. 2011–2014
and 2015–2016. 3.1.1 Determining the appropriate sample weight for analysis 2018.
. https://wwwn.cdc.gov/nchs/data/nhanes/2011-2012/analyticguidelines/analytic_
guidelines_11_16.pdf. [Accessed 19 February 2020]. .
[20] American Geriatrics Society 2019 Updated AGS Beers Criteria ® for potentially inap-
propriate medication use in older adults. J Am Geriatr Soc. 2019;67:674–94. https://
doi.org/10.1111/jgs.15767.
[21] Maust DT, Gerlach LB, Gibson A, Kales HC, Blow FC, Olfson M. Trends in central ner-
vous system-active polypharmacy among older adults seen in outpatient care in the
United States. JAMA Intern Med. 2017;177:583–5. https://doi.org/10.1001/
jamainternmed.2016.9225.
[22] Gardner JS, Blough D, Drinkard CR, Shatin D, Anderson G, Graham D, et al. Tramadol
and seizures: a surveillance study in a managed care population. Pharmacotherapy.
2000;20:1423–31. https://doi.org/10.1592/phco.20.19.1423.34854.
[23] Hassamal S, Miotto K, Dale W, Danovitch I. Tramadol: understanding the risk of se-
rotonin syndrome and seizures. Am J Med. 2018;131:1382.e1–6. https://doi.org/10.
1016/j.amjmed.2018.04.025.
[24] Fava M, Rush AJ, Thase ME, Clayton A, Stahl SM, Pradko JF, et al. 15 years of clinical
experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL.
Prim Care Companion J Clin Psychiatry. 2005;7:106–13. https://doi.org/10.4088/
PCC.v07n0305.
[25] Dhillon S. Bupropion: a review of its use in themanagement ofmajor depressive dis-
order. Drugs and Aging. 2008;68:653–89. https://doi.org/10.1007/s40266-012-
0040-1.
[26] Administration UF and D. FDA requires strong warnings for opioid analgesics, pre-
scription opioid cough products, and benzodiazepine labeling related to serious
risks and death from combined use 2016. . https://www.fda.gov/news-events/
press-announcements/fda-requires-strong-warnings-opioid-analgesics-
prescription-opioid-cough-products-and-benzodiazepine. [Accessed 9 May 2020]. .
[27] Administration UF and D. FDA warns about serious breathing problems with seizure
and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin
(Lyrica, Lyrica CR) When used with CNS depressants or in patients with lung prob-
lems 2019. . https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-
about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-
neurontin. [Accessed 9 May 2020]. .
[28] Prevention C for DC and. Drug overdose deaths n.d. . https://www.cdc.gov/
drugoverdose/data/statedeaths.html (accessed January 30, 2020).
[29] Mojtabai R. National trends in long-term use of prescription opioids.
Pharmacoepidemiol Drug Saf. 2018;27:526–34. https://doi.org/10.1002/pds.4278.
[30] Kadima NT, Kobau R, Zack MM, Helmers S. Comorbidity in adults with epilepsy —
United States, 2010. Morb Mortal Wkly Rep. 2013;62:849–53.
[31] Lader M. Benzodiazepines revisited—will we ever learn? Addiction. 2011;106:
2086–109. https://doi.org/10.1111/j.1360-0443.2011.03563.x.
[32] Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA
Psychiat. 2015;72:136–42. https://doi.org/10.1001/jamapsychiatry.2014.1763.
[33] Maust DT, Lin LA, Blow FC. Benzodiazepine use and misuse among adults in the
United States. Psychiatr Serv. 2019;70:97–106. https://doi.org/10.1176/appi.ps.
201800321.
7S.W. Terman et al. / Epilepsy & Behavior 111 (2020) 107261[34] Sirven JI. Management of epilepsy comorbidities. Continuum (Minneap Minn).
2016;22:191–203. https://doi.org/10.1212/CON.0000000000000268.
[35] Sun EC, Dixit A, Humphreys K, Darnall BD, Baker LC, MacKey S. Association between
concurrent use of prescription opioids and benzodiazepines and overdose: retro-
spective analysis. BMJ. 2017;356. https://doi.org/10.1136/bmj.j760.
[36] Dasgupta N, Funk MJ, Proescholdbell S, Hirsch A, Ribisl KM, Marshall S. Cohort study
of the impact of high-dose opioid analgesics on overdose mortality. Pain Med
(United States). 2016;17:85–98. https://doi.org/10.1111/pme.12907.
[37] Hilt RJ, Chaudhari M, Bell JF, Wolf C, Koprowicz K, King BH. Side effects from use of
one or more psychiatric medications in a population-based sample of children and
adolescents. J Child Adolesc Psychopharmacol. 2014;24:83–9. https://doi.org/10.
1089/cap.2013.0036.
[38] Sarkar S. Psychiatric polypharmacy, etiology and potential consequences.
Curr Psychopharmacol. 2016;6:12–26. https://doi.org/10.2174/
2211556005666160916124719.
[39] Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet. 2012;11:
792–802. https://doi.org/10.1016/S1474-4422(12)70153-9.
[40] Perucca P, Gilliam FG, Schmitz B. Epilepsy treatment as a predeterminant of psycho-
social ill health. Epilepsy Behav. 2009;15:S46–50. https://doi.org/10.1016/j.yebeh.
2009.03.016.
[41] Jacoby A, Snape D, Baker GA. Determinants of quality of life in people with epilepsy.
Neurol Clin. 2009;27:843–63. https://doi.org/10.1016/j.ncl.2009.06.003.
[42] Gilliam F. Optimizing health outcomes in active epilepsy. Neurology. 2002;58:S9–19.
[43] Alexander HB, Broshek DK, Quigg M. Quality of life in adults with epilepsy is associ-
ated with anticonvulsant polypharmacy independent of seizure status. Epilepsy
Behav. 2018;78:96–9. https://doi.org/10.1016/j.yebeh.2017.11.006.
[44] Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly di-
agnosed epilepsy treated with established and new antiepileptic drugs a 30-year
longitudinal cohort study. JAMA Neurol. 2018;75:279–86. https://doi.org/10.1001/
jamaneurol.2017.3949.
[45] Beghi E, Giussani G, Grosso S, Iudice A, La A, Pisani F, et al. Withdrawal of antiepilep-
tic drugs: guidelines of the Italian League Against Epilepsy. Epilelpsia. 2013;54:2–12.
https://doi.org/10.1111/epi.12305.[46] Hessen E, Lossius MI, Reinvang I, Gjerstad L. Slight improvement in mood and irrita-
bility after antiepileptic drug withdrawal: a controlled study in patients on mono-
therapy. Epilepsy Behav. 2007;10:449–55. https://doi.org/10.1016/j.yebeh.2007.01.
014.
[47] Hessen E, Mi L, Antiepileptic GL. Antiepileptic monotherapy significantly impairs
normative scores on common tests of executive functions. Acta Neurol Scand.
2009;119:194–8. https://doi.org/10.1111/j.1600-0404.2008.01109.x.
[48] Boshuisen K, Van Schooneveld MMJ, Uiterwaal CSPM, Cross JH, Harrison S, Polster T,
et al. Intelligence quotient improves after antiepileptic drug withdrawal following
pediatric epilepsy surgery. Ann Neurol. 2015;78:104–14. https://doi.org/10.1002/
ana.24427.
[49] Helmstaedter C, Elger CE, Witt JA. The effect of quantitative and qualitative antiepi-
leptic drug changes on cognitive recovery after epilepsy surgery. Seizure. 2016;36:
63–9. https://doi.org/10.1016/j.seizure.2016.02.001.
[50] Jacoby A, Johnson A, Chadwick D. Psychosocial outcomes of antiepileptic drug dis-
continuation. The Medical Research Council Antiepileptic Drug Withdrawal Study
Group. Epilepsia. 1992;33:1123–31.
[51] Meyer AC, Dua T, Ma J, Saxena S, Birbeck G. Global disparities in the epilepsy treat-
ment gap: a systematic review. Bull World Health Organ. 2010;88:260–6. https://
doi.org/10.2471/BLT.09.064147.
[52] Brooks DR, Avetisyan R, Jarrett KM, Hanchate A, Shapiro GD, Pugh MJ, et al. Valida-
tion of self-reported epilepsy for purposes of community surveillance. Epilepsy
Behav. 2012;23:57–63. https://doi.org/10.1016/j.yebeh.2011.11.002.
[53] Holden EW, Grossman E, Nguyen NT, Gunter MJ, Grebosky B, Von Worley A, et al.
Developing a computer algorithm to identify epilepsy cases inmanaged care organi-
zations. Dis Manag. 2005;8:1–14.
[54] Lacasse A,Ware MA, Bourgault P, Lanctot H, Dorais M, Boulanger A, et al. Accuracy of
self-reported prescribed analgesic medication use Quebec administrative prescrip-
tion claims databases. Clin J Pain. 2016;32:95–102. https://doi.org/10.1097/AJP.
0000000000000248.
[55] Kroenke K, Spitzer RL, Williams JBW, Löwe B. The patient health questionnaire so-
matic, anxiety, and depressive symptom scales: a systematic review. Gen Hosp Psy-
chiatry. 2010;32:345–59. https://doi.org/10.1016/j.genhosppsych.2010.03.006.
